ChemicalBook > CAS DataBase List > Deferoxamine

Deferoxamine

Product Name
Deferoxamine
CAS No.
70-51-9
Chemical Name
Deferoxamine
Synonyms
DESFEROXAMINE;dfoa;taone;entaone;ba33112;desferin;desferex;desferan;ba-29837;ba-33112
CBNumber
CB8506290
Molecular Formula
C25H48N6O8
Formula Weight
560.69
MOL File
70-51-9.mol
More
Less

Deferoxamine Property

Melting point:
139°C
Boiling point:
627.9°C (rough estimate)
Density 
1.2216 (rough estimate)
refractive index 
1.5540 (estimate)
storage temp. 
-20°C
form 
Solid
pka
9.08±0.50(Predicted)
color 
White to off-white
InChIKey
UBQYURCVBFRUQT-UHFFFAOYSA-N
SMILES
C(=O)(N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN)CCC(=O)NCCCCCN(O)C(=O)C
EPA Substance Registry System
Deferoxamine (70-51-9)
More
Less

Safety

Hazardous Substances Data
70-51-9(Hazardous Substances Data)
Toxicity
LD50 oral in mouse: 1340mg/kg
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H317May cause an allergic skin reaction

Precautionary statements

P261Avoid breathing dust/fume/gas/mist/vapours/spray.

P272Contaminated work clothing should not be allowed out of the workplace.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352IF ON SKIN: wash with plenty of soap and water.

P321Specific treatment (see … on this label).

P333+P313IF SKIN irritation or rash occurs: Get medical advice/attention.

P363Wash contaminated clothing before reuse.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
Y0001937
Product name
Deferoxamine for peak identification CRS 1
Purity
European Pharmacopoeia (EP) Reference Standard
Packaging
20 mg
Price
$236
Updated
2025/07/31
American Custom Chemicals Corporation
Product number
API0015199
Product name
DEFEROXAMINE
Purity
95.00%
Packaging
5MG
Price
$500.04
Updated
2021/12/16
American Custom Chemicals Corporation
Product number
API0015199
Product name
DEFEROXAMINE
Purity
95.00%
Packaging
1G
Price
$1428
Updated
2021/12/16
More
Less

Deferoxamine Chemical Properties,Usage,Production

Description

Deferoxamine was introduced in the 1960s for chelation of iron. It is synthesized by removing a central iron molecule from ferrioxamine B, a compound obtained from the microorganism Streptomyces pilosus. Deferoxamine binds to iron from ferritin and forms ferrioxamine, a very stable and water-soluble chelate with a characteristic reddish color.

Originator

Deferoxamine,Novartis,Germany

Uses

Deferoxamine is used for the treatment of both acute iron intoxication and chronic iron overload due to transfusiondependent anemias. It has also been used in trials for malaria treatment and for aluminum chelation in hemodialysis patients. Studies of a rat model of intracerebral hemorrhage have noted that deferoxamine treatment reduced oxidative stress from iron release, indicating a possible role in preventing damage associated with hemorrhagic strokes.

Uses

Chelating agent (iron).

Definition

ChEBI: Desferrioxamine B is an acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator. It has a role as an iron chelator, a siderophore, a ferroptosis inhibitor and a bacterial metabolite. It is a conjugate acid of a desferrioxamine B(3-).

Manufacturing Process

O-Benzylhydroxylamine hydrochloride (4.7 g, 29.7 mmol) was mixed with 5 ml of water and 11 ml of methanol at 0°C and the pH adjusted to 4.7 using 6 N KOH. The aldehyde, 4-cyanobutanal (2.6 mL, 27 mmol) was added to the hydroxylamine and the mixture allowed to warm to room temperature. The pH was maintained by addition of further 6 N KOH. After 1 h, the reaction was cooled to 0°C, and sodium cyanoborohydride (1.26 g, 20 mmol) was added. The pH was adjusted to 3 and maintained by addition of saturated HCl in methanol. When the pH stabilized, the reaction was warmed to room temperature and stirred for 3 h at a PH of 3. The reaction mixture was then poured into ether and made basic with 6 N KOH. The aqueous layer was extracted with ether (3x50 mL). The extracts were combined, washed with brine, and dried over magnesium sulfate. The solvents were removed and the resulting liquid distilled at 150°-151°C (0.6 mm) to give 4.65 g (84% of Obenzyl-N-(4-cyanobutyl)hydroxylamine. 2.8 g (13.7 mmol) of the above prepared hydroxylamine in 23 ml of pyridine and 2.1 g (20.8 mmol) of succcinic anhydride, initially heated at 100°C for 1.5 h then allowed to cool to room temperature and stirred overnight. The pyridine was removed in vacuum and the residue was dissolved in a minimal amount of chloroform, and the residue was dissolved in ether, which was extracted three times with 20% potassium bicarbonate (3x50 mL). The aqueous solutions were combined, acidified, extracted with ether, dried, filtered and evaporated; the residue was then chromotagraphed on silica gel to give 4.12 g (98%) of N-(4-cyanobutylN-(benzyloxy)succinamic acid.
2.6 g (12.75 mmol) of O-benzyl-N-(4-cyanobutyl)hydroxylamine, 17.24 mL of pyridine and 17.2 mL of acetic anhydride were stirred under argon at room temperature for 24 h. Then the excess pyridine and acetic acid anhydride were removed by vacuum. The resulting oil was taken up in chloroform, which was extracted with 1 N HCl (2x50mL), washed with sodium bicarbonate and brine, dried, over sodium sulfate, filtered and evaporated to give 3.4 g (100%) of N-(4-cyanobutyl)-N-(benzyloxy)acetamide as a light oil. 1.4 g (5.7 mmol) of this product, 2.6 g Raney nickel, 15 ml of ammonia saturated methanol and 4 ml of saturated ammonium hydroxide were cooled in a ice bath and anhydrous ammonia was allowed to bubble through the solution for 10 min. The bottle was pressurized to 50 psi with hydrogen and shook for 3 h. Then the catalyst was filtered and the solvents evaporated. The crude material was chromatografed on silica gel to gave a 1.25 g (88%) of N-(5- aminopentyl)-N-(benzyloxy)acetamide.
1 g (4 mmol), of the above acetamide, 1.46 g (4.79 mmol) of N-(4- cyanobutyl-N-(benzyloxy)succinamic acid, 1.24 g (6 mmol) of DCC and 70 mg of DMAP was cooled to 0°C for 0.55 h in 28 mL of chloroform. The mixture was allowed to warm to room temperature and stirred 24 h. Then it was again cooled to 0°C, filtered and chromatografed to yield 2.1 g (98%) of N-(4- cyanobutyl)-3-[{5-N-benzyloxy)acetamido)pentyl}carbomoyl]-Obenzylpropionohydroxamic acid. This product (1 g) was hydrogeneted by analogue with N-(4-cyanobutyl)-N-(benzyloxy)acetamide using Nickel Raney as catalyst to give 1 g (88%) N-(5-aminopentyl)-3-[{5-(N - benzyloxyacetamido)pentyl}carbomoyl]-O-benzylpropionohydroxamic acid, which produced by the reaction with DCC described above 0.78 g (88%) of N- [5-[3-[{4-cyanobutyl)(benzyloxy)-carbomoyl]propionaminoamido]pentyl}-3- [{5-(N-bebzyloxyacetamido)pentyl]-carbomoyl]-O-benzylpropionohydroxamic acid. The purity of all products confirmed with1H-NMR and elemental analyses. The last compound (0.165 g, 0.2 mmol) was reduced in methanol, 2.7 mL of 0.1 N HCl and 0.27 g of 10% Pd on C. The hydrogenation was carried out at one atmosphere of hydrogene for 7.5 hrs. The solution was filtered, the solvents were removed and the residue was washed with cold methanol, and then chloroform to give 0.1 g (84%) of product. This material had melting point 167°-168°C [Prelog, supra] and was identical to an authentic sample by 300 MHz NMR [sample of deferrioxamine B supplied by dr. Heirich H. Peter at Ciba-Geigy, Basel, Switzerland].

brand name

Desferal (Novartis).

Therapeutic Function

Pharmaceutic aid (chelating agent)

Environmental Fate

Localized infusion or injection site reactions may occur with deferoxamine administration, such as pain, urticaria and flushing of the skin. Hypersensitivity reactions have been documented with both acute and chronic administration of deferoxamine. Some of the more serious side effects include infusion rate-related hypotension, renal insufficiency, neurotoxicity, growth retardation, pulmonary toxicity, and infections. Deferoxamine may induce venous dilation when given at doses greater than 15 mg kg-1 h-1 leading to poor venous return, depressed cardiac output, and eventually hypotension. Increased levels of histamine have been noted during hypotensive episodes, although pretreatment with antihistamines has not been shown to stop the reaction. An acute decrease in glomerular filtration rate and renal plasma flow secondary to hypotension is the possible mechanism underlying the nephrotoxicity induced by deferoxamine. Depletion of iron, translocation of copper, and chelation of other trace elements including zinc may interfere with critical iron-dependent enzymes, causing oxidative damage within various tissues. These are possible mechanisms thought to be responsible for deferoxamineinduced neurotoxicity, growth retardation, and pulmonary toxicity. In vitro studies have shown that deferoxamine inhibits the synthesis of prostaglandin, hemoglobin, ferritin, collagen, and DNA. The iron–deferoxamine complex, ferrioxamine, is a growth factor for many bacteria and fungi. Deferoxamine has been associated with Yersinia enterocolitica overgrowth and fatal cases of mucormycosis with prolonged therapy.

Deferoxamine Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Deferoxamine Suppliers

Beijing Kemaiqi Medical Technology Co., LTD
Tel
010-15910349257 15910349257
Email
biandeqian@163.com
Country
China
ProdList
698
Advantage
58
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Fax
0755-28363542
Email
sales@chem-strong.com
Country
China
ProdList
18333
Advantage
56
Shanghai Macklin Biochemical Co.,Ltd.
Tel
15221275939
Fax
021-50706099
Email
shenlinxing@macklin.cn
Country
China
ProdList
15873
Advantage
55
Chizhou Kailong Import and Export Trade Co., Ltd.
Tel
Fax
-
Email
xg01_gj@163.com
Country
China
ProdList
9484
Advantage
50
Shanghai Synchem Pharma Co., ltd
Tel
21-619849051-1 18521059765
Email
synchempharma@aliyun.com
Country
China
ProdList
6468
Advantage
55
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Amadis Chemical Company Limited
Tel
571-89925085
Fax
0086-571-89925065
Email
sales@amadischem.com
Country
China
ProdList
131957
Advantage
58
Rhawn Reagent
Tel
400-400-1332688 18019345275
Fax
400-133-2688
Email
amy@rhawn.cn
Country
China
ProdList
14948
Advantage
58
Dayang Chem (Hangzhou) Co.,Ltd.
Tel
+86-0571-88938639 +8617705817739
Fax
+86-571-88938652,+86-571- 88492614
Email
info@dycnchem.com
Country
China
ProdList
52846
Advantage
58
Shaanxi Dideu Medichem Co. Ltd
Tel
+86-029-89586680 +86-18192503167
Fax
+86-29-88380327
Email
1026@dideu.com
Country
China
ProdList
8025
Advantage
58
Hubei Jusheng Technology Co.,Ltd.
Tel
18871490254
Fax
027-59599243
Email
linda@hubeijusheng.com
Country
CHINA
ProdList
28172
Advantage
58
Guangzhou Younan Technology Co., Ltd
Tel
020-82000279 18988941452
Fax
QQ:3283937693
Email
YN_research@163.com
Country
China
ProdList
3011
Advantage
58
Nanchang Tianzhen Biotechnology Co., Ltd
Tel
13758194781 13173652190
Email
522013271@qq.com
Country
China
ProdList
2395
Advantage
58
Wuhan Topule
Tel
+86-02787215551 +86-19945035818
Fax
027-87215551
Email
2936752263@qq.com
Country
China
ProdList
7985
Advantage
58
Mainchem Co., Ltd.
Tel
--
Fax
--
Email
sarah@mainchem.com
Country
China
ProdList
6547
Advantage
58
Zhengzhou Akem Chemical Co., Ltd
Tel
13303867194
Email
3001317055@qq.com
Country
China
ProdList
9681
Advantage
58
Hubei Kele Fine Chemical Co., Ltd
Tel
027-59101668 19945030958
Fax
027-59101668
Email
2881924765@qq.com
Country
China
ProdList
7937
Advantage
58
Wuhan Augda Biotechnology Co., Ltd
Tel
15071299552
Fax
QQ:262933239
Email
262933239@qq.com
Country
China
ProdList
7047
Advantage
58
Shanghai Taopu Industrial Co., LTD
Tel
159-00573766 18018507602
Email
394643792@qq.com
Country
China
ProdList
4328
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 13681763483
Email
product02@bidepharm.com
Country
China
ProdList
59936
Advantage
58
Beijing Taihe Jingming Pharmaceutical Technology Co., Ltd.
Tel
15011440205
Email
chem_w@163.com
Country
China
ProdList
304
Advantage
58
Shaanxi DIDU pharmaceutical and Chemical Co., Ltd
Tel
029-029-81120477 17792793610
Email
1033@dideu.com
Country
China
ProdList
9963
Advantage
58
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.
Tel
15387063101
Email
2881924050@qq.com
Country
China
ProdList
9958
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Xianning Shen Lan Biomedical Research and Development Co., Ltd.
Tel
18171815831
Email
1341138380@qq.com
Country
China
ProdList
4309
Advantage
58
RD International Technology Co., Limited
Tel
18024082417
Email
market@ubiochem.com
Country
China
ProdList
9835
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9765
Advantage
58
Guangdong Wengjiang Chemical Reagent Co.,Ltd.
Tel
0751-2815983 13927872582
Fax
0751-2886750
Email
2787852318@qq.com
Country
China
ProdList
8065
Advantage
58
Jiangsu Aikon Biopharmaceutical R&D Co.,Ltd
Tel
025-58851090 17714375163
Email
2881759498@qq.com
Country
China
ProdList
13011
Advantage
58
Chengdu Peter-like Biotechnology Co., Ltd.
Tel
028-81700200 13308200041
Email
2851167782@qq.com
Country
China
ProdList
11146
Advantage
58
Sangon Biotech (Shanghai) Co.,Ltd.
Tel
400-821-026
Email
Sales@sangon.com
Country
China
ProdList
6710
Advantage
58
Merck KGaA
Tel
21-20338288
Email
ordercn@merckgroup.com
Country
China
ProdList
6394
Advantage
58
Yeasen Biotechnology (Shanghai) Co Ltd
Tel
400-6111-883 13121892008
Email
marketing@yeasen.com
Country
China
ProdList
6173
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Selleck Chemicals
Tel
400-668-6834
Email
info@selleck.cn
Country
China
ProdList
6071
Advantage
58
Santa Cruz Biotechnology Inc
Tel
021-60936350
Email
scbt@scbt.com
Country
China
ProdList
6594
Advantage
58
Henan Tianfu Chemical Co.,Ltd.
Tel
+86-0371-55170693 +86-19937530512
Fax
0371-55170693
Email
info@tianfuchem.com
Country
China
ProdList
21612
Advantage
55
Zibo Hangyu Biotechnology Development Co., Ltd
Tel
+86-0533-2185556 +8615965530500
Email
nickzhang@hangyubiotech.com
Country
China
ProdList
8510
Advantage
58
XIAMEN AMITY INDUSTRY AND TRADE CO., LTD.
Tel
+8618950047208
Email
ellena@amitychem.com
Country
China
ProdList
43416
Advantage
58
Wuhan Jingkang en Biomedical Technology Co., Ltd
Tel
+8613720134139
Email
orders@jknbiochem.com
Country
China
ProdList
5221
Advantage
58
Wuhan Topule Biopharmaceutical Co., Ltd
Tel
+8618327326525
Email
masar@topule.com
Country
China
ProdList
8467
Advantage
58
GIHI CHEMICALS CO.,LIMITED
Tel
+8618058761490
Email
info@gihichemicals.com
Country
China
ProdList
49934
Advantage
58
PT CHEM GROUP LIMITED
Tel
+86-85511178;
Email
peter68@ptchemgroup.com
Country
China
ProdList
35425
Advantage
58
Shanwei Biotechnology (Shenzhen) Co., Ltd
Tel
18002535298
Country
CHINA
ProdList
135
Advantage
58
Guangzhou Zhenhao Biotechnology Co., Ltd.
Tel
13430395027
Country
CHINA
ProdList
115
Advantage
58
Henan Xianbei Biotechnology Co., Ltd.
Tel
13333869389
Country
CHINA
ProdList
140
Advantage
58
Absin Bioscience Inc.
Tel
--
Fax
--
Email
chenjw@absin.cn
Country
CHINA
ProdList
6208
Advantage
58
Proteintech China
Tel
--
Fax
--
Email
Proteintech-CN@ptglab.com
Country
CHINA
ProdList
6290
Advantage
58
Shanghai Hao Zhun Biological Technology Co., Ltd.
Tel
--
Fax
--
Email
info@zzsrm.com
Country
CHINA
ProdList
6650
Advantage
58
More
Less

View Lastest Price from Deferoxamine manufacturers

Shaanxi Dideu Medichem Co. Ltd
Product
Deferoxamine 70-51-9
Price
US $1.10/g
Min. Order
1g
Purity
99.0% min
Supply Ability
100 tons min
Release date
2021-05-25
Wuhan Topule Biopharmaceutical Co., Ltd
Product
Deferoxamine 70-51-9
Price
US $8.00/mg
Min. Order
10mg
Purity
98%
Supply Ability
50g
Release date
2023-06-13

70-51-9, DeferoxamineRelated Search:


  • deferoxamideb
  • deferoxamin
  • deferoxamine
  • deferoxamineb
  • deferoxaminum
  • deferrioxamine
  • deferrioxamineb
  • desferan
  • desferex
  • desferin
  • desferral
  • desferriferrioxaminb
  • desferrin
  • desferrioxamineb
  • dfoa
  • entaone
  • n-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(n-hydroxy
  • n’-[5-[[4-[[5-(acetylhydroxamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pen
  • n-benzoyl-ferrioxamine
  • n-benzoylferrioxamineb
  • nsc-527604
  • ButanediaMide,N4-[5-[[4-[[5-(acetylhydroxyaMino)pentyl]aMino]-1,4-dioxobutyl]hydroxyaMino]pentyl]-N1-(5-aMinopentyl)-N1-hydroxy-
  • 1-amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(n-acetylhydroxylamino)-6,11,17,
  • 22-tetraazaheptaeicosane
  • 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trih
  • 3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentone,30-amino-3,14,25-trihyd
  • 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-p
  • 30-amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pen
  • acetamido)pentyl]carbamoyl]propionohydroxamicacid
  • ba-29837
  • ba33112
  • ba-33112
  • butanediamide,n’-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)h
  • pentyl)-3-((5-(n-hydroxyacetamido)pentyl)carbamoyl)-
  • taone
  • tyl]-n-(5-aminopentyl)-n-hydroxybutanediamide
  • ydroxyamino)pentyl)-n-(5-aminopentyl)-n-hydroxy-
  • N-[5-[[4-[5-azanylpentyl(hydroxy)amino]-4-oxo-butanoyl]amino]pentyl]-N'-[5-[ethanoyl(hydroxy)amino]pentyl]-N-hydroxy-butanediamide
  • N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-keto-butanoyl]amino]pentyl]-N-hydroxy-succinamide
  • N'-[5-[acetyl(hydroxy)amino]pentyl]-N-[5-[[4-[5-aminopentyl(hydroxy)amino]-4-oxobutanoyl]amino]pentyl]-N-hydroxybutanediamide
  • N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)-pentyl)amino)-4-oxobuta
  • DESFEROXAMINE
  • DESFERROXAMINE
  • N'-[5-[[4-[[5-(Acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxysuccinamide
  • N'-{5-[ACETYL(HYDROXY)AMINO]PENTYL}-N-[5-({4-[(5-AMINOPENTYL)(HYDROXY)AMINO]-4-OXOBUTANOYL}AMINO)PENTYL]-N-HYDROXYSUCCINAMIDE
  • N1-(5-aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide
  • Deferoxamine USP/EP/BP
  • Deferoxamine B|||Desferrioxamine B
  • Deferoxamine for peak identification CRS 1
  • 70-51-9
  • C25H48N6O8